Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/II Trial of Y101D Combined With Gemcitabine and Albumin Paclitaxel in First-line Treatment of Patients With Advanced Pancreatic Cancer

NCT06266143 is registered in ClinicalTrials.gov with Wuhan YZY Biopharma Co., Ltd. as lead sponsor.

NCT NCT06266143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06266143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/II Trial of Y101D Combined With Gemcitabine and Albumin Paclitaxel in First-line Treatment of Patients With Advanced Pancreatic Cancer
Lead sponsor
Wuhan YZY Biopharma Co., Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
February 8, 2023
Completion date
January 21, 2025
Enrollment
71 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced pancreatic adenocarcinoma